Topic List : Cancer
Urine test for bladder cancer
The researchers found that by testing for fragments of cancer DNA in urine, they could find the cancer in early stages of development, when it’s easier to treat.
CAR-T cells for pediatric solid tumors
In mouse studies, a Stanford-led team has developed an engineered immune cell that eliminates several types of childhood tumors. The innovation may help patients with relapsed or metastatic disease.
Radiotherapy in less than a second
SLAC and Stanford researchers have secured funding for two projects that share one goal: to reduce the side effects of radiation therapy by vastly shrinking the length of a typical session.
Understanding ‘chemo brain’
Three types of cells in the brain’s white matter show interwoven problems during the cognitive dysfunction that follows treatment with the cancer drug methotrexate, Stanford neuroscientists have found.
No survival benefit with new cancer drug
Cisplatin chemotherapy can bring lasting adverse health effects, but a new, presumably less-toxic alternative is not as effective at promoting survival, according to a large, Stanford-led trial.
Study: Anti-CD47 cancer therapy safe
An immunotherapy conceived at Stanford appeared safe in an early clinical trial. Half of the participants responded positively to the treatment, aimed at triggering macrophages to engulf cancer cells, the researchers reported.
Clue charting cancer gene regulation
Understanding when and where proteins bind to DNA may be the ticket to identifying cancer at the cellular level, according to researchers at Stanford.
Artandi to lead Stanford Cancer Institute
A cancer biologist, Artandi studies the role of telomerase in stem cells and cancer. He replaces outgoing director Beverly Mitchell.
‘Cascade’ testing identifies relatives at risk
An online effort coupled with lower costs significantly increased the proportion of cancer patients’ relatives who chose to undergo genetic testing for cancer-associated mutations in Stanford study.
Test predicts lymphoma therapy success
Changes in circulating tumor DNA levels quickly predict how patients with diffuse large B cell lymphoma are responding to therapy, according to a Stanford-led study. Currently, patients wait months for the results.